# Vericel share price today (Vericel Corporation, VCEL)

> Vericel Corporation's earnings have grown faster than its share price. Earnings per share grew +60.0% in a year while the price moved +33.0%. VCEL · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/vcel

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $51.78 (+33.0% in a year)
- P/E: 83.9×, over 2.1 years
- Revenue (Jun 2026): $77.5 M (+22.5% on a year ago)
- Profit (Jun 2026): $2.2 M
- Operating margin: 0.6% (+3.8 points on a year ago)
- ROE: 5%, FY25
- ROIC: 8.7%, against a 9.8% cost of capital: −1.1 points
- Profit that came in as cash: 409%, last 2 years

The main question: yearly earnings per share moved +60.0% while the share price moved +33.0%. ## What is the Vericel share price today? Vericel Corporation's share price was $51.78 at the close on 5 November 2026. It has been rising for 10 weeks. That is 33.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $29 and $52, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 10 years the share price moved +2,232% while the S&P 500 moved +245%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Vericel pay? Vericel Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Vericel on? Vericel is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Vericel profitable? Vericel Corporation earned $2.2 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $16.5 M. That is 2.8% of the quarter's revenue. The same quarter a year earlier lost $553 K. 7 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $16.5 M (+59.4% on the year before). ## How much revenue does Vericel make, and is it growing? Vericel Corporation reported $77.5 M of revenue in the Jun 2026 quarter, +22.5% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 15.3% a year on average. The last full year, FY25, came in at $276 M. The last four reported quarters add to $306 M. FY25 revenue was $276 M, +16.5% on the year before. Recent pace: the last four quarters grew +23.1% on average, against 15.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +23.0%, against +19.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +240.8%, against +454.1% a year (rolling over). ## How much of every $100 of sales does Vericel keep? Vericel Corporation's operating margin was 0.6% in the Jun 2026 quarter, 3.8 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −10.4% and 4.0%. The latest quarter is within that range. Across 5 years it has been between −10.4% and 4.0%, and FY25's 4.0% is the highest of them. Why the margin moved: operating margin changed +3.8 percentage points on the year while gross margin changed −0.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Vericel's profit turning into cash? Over the last 2 years, 409% of Vericel Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $51.9 M of operating cash against $16.5 M of profit. After $27.2 M of spending on assets, $24.7 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Vericel's cash go? Vericel Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $111 M on assets over the last 3 years. Averaged over those years that is 13.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $111 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Vericel's P/E ratio, and how does it compare with its own history? Vericel Corporation's P/E is 83.9×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +60.0% while the price moved +33.0%. Earnings did better than the price, which pulled the multiple down within its own range. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Vericel business getting better or worse? Vericel Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Vericel earn on its capital? Vericel Corporation earned a ROE of 5% in FY25. That is up from a low of −9% in FY22. Its return on capital used (ROIC) is 1.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 6.0% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 6.0% net margin × 0.57× asset turnover × 1.38× leverage (assets divided by equity) ≈ 4.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 8.7% − 9.8% = −1.1 percentage points. The 9.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 8.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 3.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Vericel have too much debt? Vericel Corporation has total debt of $93.1 M against shareholder equity of $370 M as of Jun 2026, so its debt is 0.25× its equity, which is very little. Year by year, that ratio went from 0.29 in FY21 to 0.27 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Vericel shareholding pattern? 10.4% of Vericel Corporation's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Vericel from balance-sheet trouble? For Vericel Corporation, the Z-score is 8.42. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 8.42 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Vericel rank in its industry? There is no score against its industry: Vericel Corporation is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Vericel compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Vericel in size? Vericel is the 64th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: ADMA Biologics, Inc., Zai Lab and AtaiBeckley Inc. Just below it: Beam Therapeutics Inc., Xencor, Inc. and Arcus Biosciences, Inc. ### Biotechnology companies close in size

1. [ADMA Biologics, Inc.](https://www.sectoralpha.in/us/stocks/adma) $2.9 billion
2. [Zai Lab Limited](https://www.sectoralpha.in/us/stocks/zlab) $2.8 billion
3. [AtaiBeckley Inc.](https://www.sectoralpha.in/us/stocks/atai) $2.7 billion
4. Vericel Corporation $2.7 billion
5. [Beam Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/beam) $2.6 billion
6. [Xencor, Inc.](https://www.sectoralpha.in/us/stocks/xncr) $2.6 billion
7. [Arcus Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/rcus) $2.5 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [ePlus inc.](https://www.sectoralpha.in/us/stocks/plus) $2.3 billion · Software - Application
2. [Benchmark Electronics, Inc.](https://www.sectoralpha.in/us/stocks/bhe) $2.3 billion · Electronic Components
3. Vericel Corporation $2.3 billion
4. [Endeavour Silver Corp.](https://www.sectoralpha.in/us/stocks/exk) $2.3 billion · Silver
5. [Northwest Bancshares, Inc.](https://www.sectoralpha.in/us/stocks/nwbi) $2.3 billion · Banks - Regional

## What else do people ask about Vericel? ### What were Vericel's latest quarterly results? Vericel Corporation reported revenue of $77.5 M and net profit of $2.2 M for the Jun 2026 quarter. Earnings per share were $0.04. The operating margin was 0.6%, 3.8 percentage points higher than a year earlier (as of 5 November 2026). ### What is Vericel's market cap? Vericel Corporation's market capitalisation is $2.7 B at a stock price of $51.78. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Vericel performing? Vericel Corporation's share price has been rising for 10 weeks. Over the past 13 weeks it has done better than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Vericel's stock price go up? This page does not forecast Vericel Corporation's stock price. What it shows instead: the stock price is $51.78, and it has been rising for 10 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Vericel have too much debt? No, Vericel Corporation has little debt: its debt is 0.24× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 5 November 2026). ### Is Vericel's profit real cash? Yes, over the last 2 years, 409% of Vericel Corporation's reported profit came in as cash from operations. The latest year was lower at 314%, so the trend is worth watching. In FY25, operating cash was $51.9 M against reported profit of $16.5 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 5 November 2026). ### Where is Vericel in its business cycle? Vericel Corporation's FY25 operating margin was 4.0%, against a 5-year range of −10.4% to 4.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 0.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Vericel story? The main question: yearly earnings per share moved +60.0% while the share price moved +33.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Vericel a stock worth studying right now? What the numbers show: Vericel Corporation's earnings have grown faster than its share price. Earnings per share grew +60.0% in a year while the price moved +33.0%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.